RE:TriActSpeaking of shorts... Not sure if true or not, but if you have time on your hands, read the comments section of this Seeking Alpha article (I previously posted). --- https://seekingalpha.com/article/4102988-prometic-update ---- Dr. Abbott's (PhD in cell physiology from Oxford University) response(s) to another Seeking Alpha contributor (see his bio, Steve Goldman, at bottom) were helpful to me and appears to Mr. Goldman as well about his query on Bloom Burton's ?challenging? research report on PLI. Also see Pier-Luc Montgrain's comment re Bloom Burton and shorting. ---- Steven Goldman Special situations, long/short equity, Event driven investments, biotech Member Since 2015 Steven H. Goldman is a commercial litigation lawyer and senior partner in the Toronto law firm of Goldman Hine LLP. Steven graduated with a B.A., President's Medal recipient (1976, Carleton University, Ottawa, Ontario) and J.D. (1980, Queen's University, Kingston, Ontario). He is a former member of the board of directors of Tribute Pharmaceuticals Inc., a Canadian public pharmaceutical company which recently merged with Pozen Pharmaceuticals on February 5, 2016, and now known as Aralez Pharmaceuticals (Nasdaq: ARLZ),